Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Avelumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Avelumab: Sponsors, patents, clinical trial progress

Avelumab is an investigational drug.

There have been 167 clinical trials for Avelumab. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Pfizer, Merck KGaA, and National Cancer Institute (NCI).

There are twenty-one US patents protecting this investigational drug and six hundred and twenty international patents.

Recent Clinical Trials for Avelumab
Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder CancerInstitut Paoli-CalmettesPhase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2
Intratumoral Microdosing of TAK-981 in Head and Neck CancerTakedaEarly Phase 1

See all Avelumab clinical trials

Clinical Trial Summary for Avelumab

Top disease conditions for Avelumab
Top clinical trial sponsors for Avelumab

See all Avelumab clinical trials

US Patents for Avelumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Avelumab   See Pricing Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   See Pricing
Avelumab   See Pricing Methods of using OX40 ligand encoding polynucleotides ModernaTX, Inc. (Cambridge, MA)   See Pricing
Avelumab   See Pricing Combinations of mRNAs encoding immune modulating polypeptides and uses thereof ModernaTX, Inc. (Cambridge, MA)   See Pricing
Avelumab   See Pricing Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors Immunomedics, Inc. (Morris Plains, NJ)   See Pricing
Avelumab   See Pricing Method of treating pancreatic cancer ChemoCentryx, Inc. (Mountain View, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Avelumab

Drugname Country Document Number Estimated Expiration Related US Patent
Avelumab European Patent Office 3313818 2035-06-26   See Pricing
Avelumab Japan 2018527302 2035-06-26   See Pricing
Avelumab World Intellectual Property Organization (WIPO) 2016210262 2035-06-26   See Pricing
Avelumab European Patent Office 3394093 2035-12-23   See Pricing
Avelumab World Intellectual Property Organization (WIPO) 2017112943 2035-12-23   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.